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We compared the effects of calcitriol and doxercalciferol, in
combination with either calcium carbonate or sevelamer,
on bone, mineral, and fibroblast growth factor-23 (FGF-23)
metabolism in patients with secondary hyperparathyroidism.
A total of 60 pediatric patients treated with peritoneal
dialysis were randomized to 8 months of therapy with either
oral calcitriol or doxercalciferol, combined with either calcium
carbonate or sevelamer. Bone formation rates decreased
during therapy and final values were within the normal range
in 72% of patients. A greater improvement in eroded surface
was found in patients treated with doxercalciferol than in
those given calcitriol. On initial bone biopsy, a mineralization
defect was identified in the majority of patients which did not
normalize with therapy. Serum phosphate concentrations
were controlled equally well by both binders, but serum
calcium levels increased during treatment with calcium
carbonate, and serum parathyroid hormone levels were
decreased by 35% in all groups. Baseline plasma FGF-23
values were significantly elevated and rose over fourfold
with calcitriol and doxercalciferol, irrespective of phosphate
binder. Thus, doxercalciferol is as effective as calcitriol in
controlling serum parathyroid hormone levels and
suppressing the bone formation rate. Sevelamer allows
the use of higher doses of vitamin D. Implications of these
changes on bone and cardiovascular biology remain to be
established.
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Despite therapy with oral calcitriol, secondary hyperpar-
athyroidism (21HPT) remains the most common lesion of
renal osteodystrophy in pediatric patients with end-stage
renal disease.1 Untreated, 21HPT leads to altered bone
histology, bone fragility, skeletal deformities, growth retarda-
tion, and cardiovascular calcifications.2,3 Therapy with
large thrice-weekly doses of calcitriol in combination with
calcium-based binders effectively reduces parathyroid hor-
mone (PTH) levels and lowers bone formation.4 However,
this form of therapy may also lead to adynamic renal
osteodystrophy,5 increased severity of growth retardation,6
hypercalcemia and/or hyperphosphatemia, and progressive
vascular calcification.7–9 To minimize these side effects,
vitamin D sterols, such as 19-nor-1,25 dihydroxyvitamin D2
(paricalcitol) and 1-a-hydroxyvitamin D2 (doxercalciferol,
1aD2), and calcium-free phosphate binders, such as sevela-
mer hydrochloride and lanthanum carbonate, have been
approved for clinical use in the United States.
Over the past decade, these new therapies have become
integral to the management of chronic kidney disease (CKD)
mineral and bone disorder. Indeed, both 1aD2 and
paricalcitol suppress PTH secretion,1,2 whereas sevelamer
and lanthanum are effective in controlling serum phosphate
while preventing increases in serum calcium.2–4 Although the
effects of sevelamer and lanthanum on skeletal histology have
been evaluated, both in adult2,5 and pediatric10 dialysis
patients, currently there are no studies in humans comparing
differences in the effects of calcitriol and any of the new
vitamin D sterols on the skeleton. Moreover, over the last few
years, the role of fibroblast growth factor-23 (FGF-23) in the
development and treatment of 21HPT,6–8 progression of renal
disease,11 cardiovascular disease,12,13 overall risk of morta-
lity,14 and bone metabolism15 in patients with CKD has been
increasingly recognized. Therapy with 1,25(OH)2vitamin
D appears to be the most potent stimulator of FGF-23
synthesis;12,13 however, there is limited knowledge of the
response of FGF-23 to the treatment of 21HPT and whether
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the FGF-23 response differs between vitamin D sterols. Thus,
this study was designed to prospectively compare the effects
of 1aD2 and calcitriol therapy on the control of the
biochemical and skeletal lesions of 21HPT and on circulating
FGF-23 levels during treatment with either a calcium-based
binder or sevelamer hydrochloride in pediatric patients
treated with peritoneal dialysis.
RESULTS
Study participants: clinical characteristics and baseline
vitamin D status
A total of 60 patients (30 males, 30 females) aged 13.9±0.5
years were enrolled in the study (Table 1). These patients,
their biochemical characteristics, and vitamin D sterol doses
have been previously described.16 The average time on
dialysis at initiation of study was 1.0±0.2 years. Of these,
11 subjects had previously undergone renal transplantation
and were receiving treatment with dialysis for at least
6 months before the beginning of the study; none of them
were treated with immunosuppressive agents during the
preceding 6 months. A total of 51 patients completed the
study, whereas 9 terminated early (5 from group 1, 2 from
group 2, 1 from group 3, and 1 from group 4), as per
protocol, because of either renal transplantation (n¼ 5) or
medication noncompliance (n¼ 4). Neither baseline bio-
chemical nor bone parameters differed in the nine who were
terminated early from those who completed the study.
Baseline serum 25(OH)vitamin D levels were below 20 ng/ml
in all four treatment groups, only one subject had a baseline
value 430 ng/ml (Table 1).
Response of bone histology to therapy
Baseline static and dynamic bone variables did not differ
between the four groups (Table 2). As per study design, all
patients had either increased rates of bone formation and/or
marrow fibrosis at the start of the study. Bone formation rate
(BFR) declined equally in all four treatment groups
throughout the course of the study, and values were in the
normal range in 72% of the patients on follow-up bone
biopsies. Only one patient developed adynamic bone. Eroded
surface, which did not differ between the four groups at
baseline, decreased in all patients treated with 1aD2 while
Table 1 | Demographic data
1aD2+CaCO3
(n=16)
1aD2+sevelamer
(n=14)
Calcitriol+CaCO3
(n=16)
Calcitriol+sevelamer
(n=14)
Age (years) 14.2±0.9 14.5±1.0 12.0±3.0 15.0±0.6
Gender (M/F) 10/6 7/7 9/7 4/10
Time on dialysis (years) 0.8±0.2 1.1±0.3 1.1±0.5 1.0±0.2
Etiology of ESRD (n)
Obstructive/dysplastic 4 5 5 6
Glomerular 9 5 5 3
Unknown 3 4 6 5
Previous transplants (n) 1 4 3 3
Dianel concentration (%) 2.5±0.1 2.5±0.1 2.5±0.0 2.5±0.1
Baseline 25(OH)vitamin D level (pg/ml) 15.7±2.7 15.0±2.7 17.1±2.8 15.2±1.9
Abbreviations: 1aD2, doxercalciferol; CaCO3, calcium carbonate; ESRD, end-stage renal disease; F, female; M, male.
Table 2 | Bone histomorphometry
1aD2+CaCO3 1aD2+sevelamer Calcitriol+CaCO3 Calcitriol+sevelamer Normal
Initial Final Initial Final Initial Final Initial Final values27,52
Turnover
Bone formation rate/bone surface (BFR/BS;
mm3/mm2 per day)
124±41 45±22a 103±41 53±29a 152±77 62±52a 101±70 60±27a 8–73.4
Eroded surface/bone surface (ES/BS; %) 10.3±3.2 7.7±3.5a 10.6±2.7 7.3±4.5a 10.3±3.0 8.6±3.3 8.4±3.1 7.9±2.7 0.5–4.3
Mineralization
Osteoid volume/bone volume (OV/BV; %) 15.3±6.0 8.9±4.3a 15.3±6.1 10.8±3.0a 17.6±9.0 8.2±5.2a 13.1±6.6 11.1±5.5 0.2–5.8
Osteoid surface/bone surface (OS/BS; %) 54.9±16.5 54.8±29.1 54.3±12.4 44.3±6.8a 56.3±11.6 43.8±28.8a 49.5±15.4 47.4±15.5 4.3–31.7
Osteoid thickness (O.Th; mm) 19.5±4.0 14.9±3.8a 21.1±4.8 17.7±2.7 22.0±3.1 16.3±5.9a 21.8±4.9 18.2±2.7 2.0–13.2
Osteoid maturation time (OMT; day) 19.6±6.8 16.6±7.8 19.7±8.0 22.7±9.9 18.4±6.1 19.8±8.2 22.5±8.5 21.4±4.0 1.2–11.5
Mineralization lag time (MLT; day) 41.3±25.2 75.5±40.1a 46.8±28.6 74.0±43.4 36.4±19.6 82.2±109.5 60.6±48.7 61.9±30.8 2.3–63.8
Volume
Bone volume/tissue volume (BV/TV; %) 28.0±7.2 26.0±7.5 30.9±6.3 28.2±4.6 28.9±8.0 30.3±11.5 33.4±5.3 29.9±4.8 8.9–34.4
Abbreviations: 1aD2, doxercalciferol; CaCO3, calcium carbonate.
aSignificant change from baseline (Po0.05).
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remaining unchanged in patients treated with calcitriol; this
finding was irrespective of the type of phosphate binder
therapy (Table 2).
Static indices of mineralization, including osteoid
volume/bone volume, osteoid surface/bone surface, and
osteoid thickness, did not differ at baseline between groups
and values for each parameter declined in all four groups.
A greater improvement in osteoid volume was observed in
patients treated with calcium carbonate (CaCO3), regardless
of vitamin D sterol, than in patients treated with sevelamer
(Table 2). Mineralization time, as measured by osteoid
maturation time, was abnormal in the majority of patients at
baseline and did not improve during therapy, whereas
mineralization lag time increased. No differences in these
parameters were observed amongst the four treatment groups
either at baseline or after 8 months of treatment (Table 2).
Bone volume was normal or increased in all patients and
did not change throughout the course of the study, regardless
of therapy.
Response of serum biochemical parameters to therapy
As previously reported,16 initial serum calcium levels were
similar between the four groups; however, values rose
progressively in both groups treated with CaCO3 while
remaining unchanged in sevelamer-treated patients
(Figure 1). By the end of the study, values in patients
receiving CaCO3 were higher than in either group of
sevelamer-treated subjects (Figure 1). In total, 48 episodes
of hypercalcemia (serum calcium X10.2mg/dl) occurred in
CaCO3-treated subjects as compared with 17 episodes in
those receiving sevelamer (Po0.01). No differences in serum
calcium levels or episodes of hypercalcemia were found
between calcitriol and 1aD2 therapies.
Overall, baseline serum phosphorus levels were
6.3±0.1mg/dl; values declined in the initial month of the
trial and remained within target range in all groups
throughout the study. Episodes of hyperphosphatemia did
not differ between the groups during follow-up period
(Figure 2). The dietary phosphorus intake throughout the
study averaged 815±43mg per day and values were similar
between groups. The calcium–phosphorus ion product was
persistently below 55mg2/dl2 in all groups. Baseline serum
bicarbonate levels did not differ between groups; however,
final values were 24.8±0.6mEq/l and 22.5±0.5mEq/l
in CaCO3- and sevelamer-treated patients, respectively
(Po0.05).
Baseline PTH levels were 940±55 pg/ml and values did
not differ between groups. As previously demonstrated,16
PTH values decreased between months 3 through to 5 of
therapy, reaching a plateau by month 6. By the end of the
study, values had declined by an average of 34% (Po0.01) in
all treatment groups (Figure 3a and 3b). Initial serum alkaline
phosphatase levels were 397±36 IU/l, values did not differ
between groups and declined similarly in all groups; final
values were 259±32 IU/l (Po0.01 from baseline; nonsigni-
ficant between groups).
Median initial FGF-23 levels were 91 pg/ml (interquartile
(IQ) range: 43–325) and 842 RU/ml (IQ range: 194–4186), as
measured by the intact assay and C-terminal assays,
respectively. Anuric subjects displayed higher baseline FGF-23
values than did patients with any degree of residual urine
output; median baseline intact FGF-23 levels were 266 pg/ml
(IQ range: 50–778) and 68 pg/ml (IQ range: 44–204) in anuric
individuals and in those with residual renal function
(Po0.01), respectively, whereas baseline values by the
C-terminal assay were 3389 RU/ml (IQ range: 1012–9623)
and 318 RU/ml (IQ range: 160–1248; Po0.01) in the two
patient subsets, respectively. FGF-23 levels measured by the
two different assays correlated throughout the course of
treatment (r¼ 0.77, Po0.01), levels did not differ between
groups, and values increased by 428±136% (intact assay)
and 638±178% (C-terminal assay; Po0.01 from baseline,
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Figure 1 | Serum calcium (S-Ca) levels throughout the course
of the study by treatment group. Treatment groups: (1)
1aD2þCaCO3 (closed diamonds), (2) 1aD2þ sevelamer
(open diamonds), (3) calcitriolþCaCO3 (closed squares), and (4)
calcitriolþ sevelamer (open squares). Asterisk indicates Po0.01
from baseline and from sevelamer-treated patients. 1aD2,
doxercalciferol; CaCO3, calcium carbonate.
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Figure 2 | Serum phosphate (S-Phos) levels throughout the
course of the study by treatment group. Treatment groups:
(1) 1aD2þCaCO3 (closed diamonds), (2) 1aD2þ sevelamer
(open diamonds), (3) calcitriolþCaCO3 (closed squares), and
(4) calcitriolþ sevelamer (open squares). 1aD2, doxercalciferol;
CaCO3, calcium carbonate.
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both assays), irrespective of baseline FGF-23 value or residual
renal function (Figure 4a and b). Similar increments in
FGF-23 levels were observed between calcitriol and 1aD2
treatment groups, irrespective of phosphate binder therapy.
No relationship was observed between the dose of vitamin D
sterol and the magnitude of increase in FGF-23.
Dosages of phosphate binders and active vitamin D sterols
according to treatment group
At the initiation of the trial, the average doses of CaCO3
were 4.3±1.4 g/day and 3.4±1.1 g/day in calcitriol- and
1aD2-treated patients, respectively (nonsignificant); doses of
sevelamer were 4.7±0.7 g/day and 5.9±0.9 g/day in calcitriol
and 1aD2 groups, respectively (nonsignificant). Final phos-
phate binder doses did not differ between groups and doses
increased by an average of 54±19% in all patients during the
course of the study. Patients treated with CaCO3 ingested
an average of 2.8±0.1 g/day of elemental calcium from
phosphate binders. Four sevelamer-treated patients ingested
an average of 1.1±0.1 g/day of elemental calcium during
months 5 through to 8 of the study in order to maintain
serum calcium levels above 8.2mg/dl.
Vitamin D sterol doses increased monthly during the first
4 months and reached stable dosage in the last 4 months of
the study (Figure 5). Patients treated with CaCO3 received an
average dose of 4.8±0.6 mg of 1aD2 or 1.4±0.1 mg of
calcitriol, and those given sevelamer received either
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Figure 3 |Plasma PTH levels throughout the course of treatment. (a) Plasma PTH levels throughout the course of the study by treatment
group and (b) plasma PTH levels expressed as percent change from baseline among the four treatment groups. Treatment groups:
(1) 1aD2þCaCO3 (closed diamonds), (2) 1aD2þ sevelamer (open diamonds), (3) calcitriolþCaCO3 (closed squares), and (4) calcitriolþ sevelamer
(open squares). Asterisk indicates Po0.01 from baseline. 1aD2, doxercalciferol; 1st PTH-IMA, first-generation parathyroid hormone
immunometric assay; CaCO3, calcium carbonate.
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Figure 5 |Vitamin D sterol doses (expressed in calcitriol
equivalents) throughout the course of the study by treatment
group. Treatment groups: (1) 1aD2þCaCO3 (closed diamonds),
(2) 1aD2þ sevelamer (open diamonds), (3) calcitriolþCaCO3
(closed squares) and (4) calcitriolþ sevelamer (open squares).
1aD2, doxercalciferol; CaCO3, calcium carbonate.
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Figure 4 |Plasma FGF-23 levels throughout the course of treatment. (a) Plasma intact fibroblast growth factor-23 (FGF-23) levels throughout
the course of the study by treatment group and (b) plasma C-terminal FGF-23 levels throughout the course of the study by treatment group.
Treatment groups: (1) 1aD2þCaCO3 (closed diamonds), (2) 1aD2þ sevelamer (open diamonds), (3) calcitriolþCaCO3 (closed squares),
and (4) calcitriolþ sevelamer (open squares). Asterisk indicates Po0.01 from baseline. 1aD2, doxercalciferol; CaCO3, calcium carbonate.
Kidney International (2011) 79, 112–119 115
K Wesseling-Perry et al.: Vitamin D sterols and bone o r ig ina l a r t i c l e
5.1±0.5 mg of 1aD2 or 2.3±0.1 mg of calcitriol. To compare
maintenance doses of vitamin D between patients treated
with different phosphate binders, 1aD2 dose was converted to
a calcitriol-equivalent dose using the formula: calcitriol-
equivalent dose¼ 1aD2 dose/5 (ref. 17). As previously
reported,16 patients treated with sevelamer were found to
have received higher calcitriol-equivalent doses of vitamin D
sterols than those treated with CaCO3 during the last 4
months of therapy (Po0.05).
DISCUSSION
This trial, the first to compare the effects of calcitriol therapy
with one of the new vitamin D sterols, 1aD2, in combination
with either CaCO3 or sevelamer on bone histology, demon-
strated equivalent improvement in the skeletal and biochem-
ical lesions of 21HPT in all four treatment arms in pediatric
patients treated with continuous cycling peritoneal dialysis.
With a total of 51 patients completing 8 months of the trial,
this study is one of few trials to achieve a sample size
considered by current KDIGO (Kidney Disease: Improving
Global Outcomes) recommendations as adequate to assess
changes in bone histomorphometry, based on different
therapeutic regimens.18 BFR, the primary end point,
decreased during therapy in all treatment groups, and final
values were within the normal range in 72% of the patients. A
greater improvement in eroded surface was found in patients
treated with 1aD2 than in those given calcitriol, regardless of
the phosphate binder. A mineralization defect was identified
in the majority of patients on initial bone biopsy and,
although treatment with CaCO3 resulted in greater improve-
ments in osteoid accumulation than did therapy with
sevelamer, no treatment arm was able to normalize skeletal
mineralization. Serum phosphate concentrations were con-
trolled equally well by both binders; however, as previously
shown, serum calcium concentrations increased during
treatment with CaCO3, while remaining unchanged in those
treated sevelamer.16 Serum PTH and alkaline phosphatase
levels were suppressed to a similar degree in all groups despite
differences in serum calcium levels, but patients treated with
sevelamer received higher doses of vitamin D sterols. At
baseline, plasma FGF-23 values were elevated; values rose
by a similar degree in all four treatment groups during the
follow-up period, irrespective of the type of vitamin D sterol
therapy used and despite no increases in serum phosphate
concentration.
Several studies have consistently demonstrated the effec-
tiveness of calcitriol, paricalcitol, and 1aD2 in suppressing
serum PTH levels,19–22 and recent studies have evaluated the
effects of different phosphate binders and calcimimetic
agents, when used in combination with active vitamin D
sterols, on bone histology in adult dialysis patients with
various subtypes of renal osteodystrophy.23,24 However, this
is the first study to prospectively compare the specific effects
of two different vitamin D sterols on the skeletal lesions of
21HPT. Increased levels of calcium were observed in patients
treated with CaCO3, which may have contributed to
declining PTH values; however, a similar degree of PTH
reduction was observed in sevelamer-treated patients, despite
stable serum calcium levels. These patients received higher
doses of active vitamin D sterols, suggesting that sevelamer
may enhance the margin of safety for the use of active
vitamin D sterols. At doses that result in equivalent
suppression of PTH, both oral 1aD2 and calcitriol, when
given in intermittent, thrice-weekly dosing, suppressed
bone formation to a similar degree. Interestingly, therapy
with 1aD2 suppressed bone erosion to a greater degree than
did calcitriol, regardless of the type of phosphate binder. The
mechanism underlying this difference has yet to be explained,
but may be due to differences in sterol bioavailability. Indeed,
the biological actions of 1aD2 are largely dependent on the
formation of 1,25(OH)2D2 after 25-hydroxylation by the
liver, leading to sustained circulating levels of 1,25(OH)2D2,
in contrast to the fluctuating values of 1,25(OH)2D3
associated with intermittent calcitriol administration.25,26
Although further studies are needed to compare the
pharmacodynamic properties of these two sterols, differential
activation of the receptor activator of nuclear factor-kB
ligand/osteoprotegerin system and osteoclastogenesis may
have a role.
The application of the TMV (turnover, mineralization,
volume) classification of renal osteodystrophy to bone
histomorphometric analyses, in accordance with current
guidelines,18 identified a baseline mineralization defect in the
vast majority of pediatric dialysis patients with 21HPT, which
persisted despite normalization of BFR. Although increased
circulating PTH levels, by activating osteoblast activity,
stimulate the formation of unmineralized osteoid and thus
increase the static amount of osteoid visualized on bone
biopsy, patients in this study also displayed prolonged
mineralization time periods. Osteoid volume and thickness
improved as PTH levels declined; however, values remained
above the upper limit of normal in all groups, while dynamic
parameters of mineralization, including osteoid maturation
time and mineralization lag time, remained abnormal and
unchanged from baseline. The prevalence of mineralization
defects in the current cohort contrasts markedly with the
findings from a recent study in the adult dialysis population,
in which mineralization defects were found to be rare.23
Although a low intake of dietary calcium may contribute to
defective skeletal mineralization in the growing child, it is
interesting to note that serum calcium levels were inversely
related with indices of mineralization. However, even patients
treated with calcium-based binders, who ingested quantities
of elemental calcium far exceeding the daily-recommended
intake, failed to normalize bone mineralization after
8 months of therapy. Thus, defective mineralization is a
multifactorial process that may involve 25(OH)vitamin D
deficiency and altered FGF-23 metabolism.27,28 Indeed,
in this study, only one subject had a serum 25(OH)vitamin
D level 430 ng/ml; the remainder were either vitamin D
insufficient or deficient according to the current diagnostic
criteria.29,30 In light of data suggesting that treatment with
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25(OH)vitamin D is effective in ameliorating defective
mineralization in pediatric patients with predialysis CKD,31
such a degree of 25(OH)vitamin D deficiency may have had a
critical role in the prevalence of mineralization defects in this
study. Alternatively, alterations in bone FGF-23 and dentin
matrix protein 1 (DMP-1) expression, both of which have
been related to alterations in skeletal mineralization in
children with CKD, may also contribute.28
In the past, intermittent oral calcitriol therapy combined
with calcium-based binders has been associated with over-
suppression of bone turnover, despite the PTH levels that
were consistent with 21HPT.5,32 In this study, BFRs normal-
ized in the majority of patients and final PTH levels ranged
from 357 to 610 pg/ml. Such values are consistent with
current KDIGO PTH guidelines, which suggest that values as
high as nine times the upper limit of the normal range may
be associated with normal rates of bone formation in dialysis
patients.18 The adjustment of vitamin D therapy according to
concurrent target levels of serum calcium, phosphorus, and
PTH, as performed in the current trial, provides evidence
that bone turnover can be normalized while preventing the
development of adynamic bone and its consequences of
growth retardation,6 hypercalcemia, and progressive vascular
calcification.7
Consistent with previous studies,33,34 baseline plasma
FGF-23 levels were markedly elevated in the current cohort of
patients. Dietary phosphate, serum phosphate, and
1,25(OH)2D3 are key regulators of FGF-23 production and
several studies have demonstrated that different therapeutic
regimens for the treatment of 21HPT lead to changes in
circulating FGF-23 values. Indeed, FGF-23 levels decrease in
response to sevelamer HCl treatment in all stages of
CKD,35,36 as well as in response to calcimimetic therapy in
CKD stage 5.37 In this study, increased values of FGF-23 were
observed throughout the course of therapy in all treatment
groups, despite stable serum phosphorus concentrations,
likely reflecting the known effect of vitamin D sterols on
FGF-23 secretion.38–41 The clinical implications of these
increasing FGF-23 values remain to be established, as therapy
with active vitamin D sterols provides a survival benefit that
is independent of serum calcium, phosphorus, and PTH
levels in dialysis patients.42–44 However, the increases in FGF-
23 levels which accompany vitamin D sterol therapy, may
prove detrimental to long-term survival; indeed, elevated
FGF-23 values have been associated with left ventricular
hypertrophy,45 vascular calcification,13 and an increased
mortality rate12 in the adult dialysis population. This paradox
highlights the needs for future prospective randomized trials,
evaluating the end-organ effects of vitamin D sterol therapy
and FGF-23 levels in patients treated with maintenance
dialysis.46
In conclusion, this study demonstrates that 1aD2, when
used in combination with either CaCO3 or sevelamer
hydrochloride, is as effective as calcitriol in controlling serum
PTH levels and suppressing BFR. Patients treated with
sevelamer received higher doses of active vitamin D without
inducing changes in serum calcium levels.16 Mineralization
defects were highly prevalent in the pediatric dialysis
population and these defects were not corrected with vitamin
D sterol and phosphate binder therapies. Thus, altered
skeletal mineralization in pediatric dialysis patients is a
multifactorial process that may be complicated by alterations
in FGF-23 metabolism and 25(OH)vitamin D deficiency.
Therapy with both calcitriol and 1aD2 resulted in similar
increases in FGF-23, irrespective of phosphate binder medica-
tion. The implications of these increasing FGF-23 levels on
bone and vascular disease in end-stage kidney disease remain
to be established, but may have implications on skeletal
mineralization,27 vascular calcification,13 and mortality.12
METHODS
All potential study candidates were medically stable patients, aged
2–21 years, who were treated with continuous cycling peritoneal
dialysis and had serum PTH levels4400 pg/ml, as determined by a
first-generation immunometric PTH assay (Nichols, San Clemente,
CA, USA),47 as has been previously reported.10,16 After a 4-week
withdrawal period from daily oral calcitriol therapy, study
candidates were admitted to the UCLA General Clinical Research
Center, and bone biopsies were obtained from the anterior iliac crest
using a modified Bordier trephine after double tetracycline labeling.
Potential subjects were eligible for randomization if they displayed
bone histomorphometric evidence of 21HPT, as has been previously
described.10,16 Exclusion criteria included previous history of poor
medication compliance; parathyroidectomy within the past 12
months; concurrent treatment with immunosuppressive agents,
growth hormone, or other bone pathology not related to 21HPT.
Patients were removed from the study, per protocol, in the event of
renal transplantation, medication noncompliance (defined as a
serum phosphorus level 47mg/dl for 3 consecutive months),
change in dialytic modality, and psychosocial factors, as determined
by medical staff. This study was approved by the UCLA Human
Subjects Protection Committee and consent forms were obtained
from all patients and/or parents/guardians.
Study design
Using a 2 2 longitudinal factorial study design, a total of 60
patients with high-turnover bone disease were randomly allocated to
one of four treatment regimens: group 1: 1aD2±CaCO3 (n¼ 16);
group 2: 1aD2±sevelamer (n¼ 14); group 3: calcitriol±CaCO3
(n¼ 16); and group 4: calcitriol±sevelamer (n¼ 14). A flowchart of
the overall study is displayed in Figure 6. Initial doses of vitamin D
sterols were based on PTH levels; therapy was given thrice-weekly
orally at bedtime.10,16 Doses were titrated upward every 4 weeks to
achieve a target PTH level between 300 and 400 pg/ml, while
maintaining serum calcium levels between 8.4 and 10.2mg/dl and
phosphorus between 4 and 6mg/dl. Vitamin D dosages were kept
constant when PTH levels fell below 500 pg/ml and serum calcium
and phosphorus levels were within the target range; vitamin D sterol
therapy was withheld for serum calcium values410.2mg/dl and/or
serum phosphorus levels 46.0mg/dl.
The initial dose of CaCO3 was based on the previous regimen,
whereas the initial dose of sevelamer was extrapolated from the
CaCO3 dosage;
48 phosphate-binding therapy was titrated to
maintain serum phosphorus between 4.0 and 6.0mg/dl.10,16 In
patients who were treated with sevelamer, 1000mg of elemental
calcium was added at bedtime if serum calcium levels were
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o8.2mg/dl. The dialysate calcium concentration was 2.5mEq/l
(Dianel; Baxter, Deerfield, IL, USA) and dextrose concentrations
were determined according to ultrafiltration requirements. Serum
levels of calcium, albumin, and phosphorus were obtained at
baseline and biweekly throughout the study; serum alkaline
phosphatase, PTH, and FGF-23 were determined monthly. Serum
25(OH)vitamin D values were measured only at baseline. Serum
calcium, albumin, phosphorous, and alkaline phosphatase concen-
trations were determined by Technicon Autoanalyzer II (SEAL
Analytical Mequon, WI, USA).10,16 Serum calcium levels were
corrected for serum albumin levels using the formula: corrected
calcium¼measured calcium±(0.8 4(serum albumin)). Serum
25(OH)vitamin D values were measured by radioimmunoassay.49
PTH levels were determined by the UCLA Clinical Laboratory using
a 1st generation immunometric PTH assay from Nichols. Plasma
FGF-23 levels were determined by two assays, termed ‘intact’ and
‘C-terminal’ assays (Immutopics, San Clemente, CA, USA).27 Bone
quantitative histomorphometry analysis was performed as has been
previously described.27 As recommended by KIDGO,18 parameters
of bone turnover, mineralization, and volume 50 are reported with
the terminology established by the Nomenclature Committee of the
American Society of Bone and Mineral Research.51
Statistical design and analyses
The primary end point was change in BFR. Power was based on
reduction of log(BFR) for the calcitriol group to have a mean
mc¼1.3 and for 1aD2 a mean md¼0.52, with a common
standard deviation of 1.1.32 To achieve a power b¼ 0.80 with an
a¼ 0.05, a final sample size of n¼ 16 per cell was estimated. Given
an expected dropout rate of 20%, recruitment was aimed
at achieving n¼ 20 per cell (n¼ 80, overall) to achieve a total of
64 patients completing the study. After 51 subjects had completed
the trial, futility analysis demonstrated that the addition of
13 patients would have o20% power to detect any interaction
between treatment arms; thus, the study was terminated.
Secondary end points were (1) time trends of serum calcium,
phosphorus, alkaline phosphatase, FGF-23, PTH levels, doses of
vitamin D sterols, and phosphate binders and (2) bone histomor-
phometric parameters of mineralization and volume. Analyses of
efficacy were based on the intent-to-treat principle. Missing values
were imputed by carrying forward the last observation. Baseline and
final biochemical values were expressed as either mean±s.e.m. or
median (interquartile range). Comparisons of changes between
groups were corrected for baseline for all parameters. Pearson
correlation coefficients were used to assess the relationship between
biochemical parameters. Statistical analysis was performed using
SAS software (SAS Institute, Cary, NC, USA) and all tests were
two-sided with significance level of Po0.05.
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